Terminalia arjuna is a large deciduous tree of the Combretaceae family, and its stem bark is an official Ayurvedic drug. The Ayurvedic Pharmacopoeia of India identifies the bark as Arjuna, describes it as hridya—traditionally regarded as beneficial to the heart—and lists hridroga among its therapeutic uses. These traditional indications provide an Ayurvedic basis for its use, but they do not by themselves establish effectiveness for modern diagnoses such as coronary artery disease or heart failure.

Modern clinical research has examined arjuna bark in chronic stable angina, chronic heart failure, lipid abnormalities and coronary-risk markers. The human evidence is encouraging in places but remains limited by small samples, short treatment periods, older study designs and a lack of trials measuring heart attack, stroke, hospitalization or cardiovascular death. Arjuna should therefore be considered, at most, a clinician-supervised adjunct rather than a replacement for established cardiac care.

Ayurvedic Identity and Classical Profile

The Ayurvedic Pharmacopoeia of India, Part I, Volume II, gives a specific profile for Terminalia arjuna stem bark. This profile is preferable to generalized descriptions that assign additional tastes, qualities or doshic actions without a clear classical or pharmacopoeial source.

The term hridya should be understood as a traditional pharmacodynamic designation, not as proof that the bark increases cardiac contractility or reverses structural heart disease. Likewise, hridroga is an Ayurvedic disease category and should not be treated as an exact synonym for every modern cardiovascular diagnosis.

Active Constituents and Mechanistic Evidence

The pharmacopoeial monograph identifies tannins as constituents of the bark. Phytochemical investigations and reviews additionally report triterpenoids, flavonoids, glycosides, sterols and polyphenolic compounds. The composition varies with plant material, extraction method and product standardization.

Preclinical studies describe antioxidant, anti-inflammatory, endothelial, platelet and myocardial effects, but these findings do not justify describing arjuna as a botanical equivalent of digoxin or any other cardiac drug. A 2015 study in stable coronary artery disease evaluated Terminalia arjuna as an adjunct and reported changes in inflammatory and immune markers; it did not test isolated arjunolic acid as a proven treatment for clinical events.

Clinical Evidence: Chronic Stable Angina

The best-known angina studies suggest possible symptom and exercise-test benefits, yet the total evidence remains too uncertain for a firm therapeutic recommendation. The most informative individual trial was short, and the later systematic review judged the underlying studies methodologically weak.

The 2002 Crossover Trial

Bharani and colleagues published a randomized, double-blind, placebo-controlled crossover study in the Indian Heart Journal in 2002 (PMID: 12086380). It enrolled 58 men with chronic stable angina and exercise-induced ischemia. Participants received arjuna bark extract 500 mg every eight hours, isosorbide mononitrate 40 mg daily and placebo for one week each, with washout periods between treatments.

• Angina frequency and use of rescue isosorbide dinitrate were lower during arjuna treatment than during placebo.
• Treadmill measures, including exercise duration and time to ischemic changes, improved versus placebo.
• The measured clinical and treadmill outcomes did not differ significantly between arjuna and isosorbide mononitrate during the brief treatment periods.
• No important adverse effect was reported during the arjuna phase.

The trial supports a short-term signal for symptom relief, not equivalence to nitrate therapy in routine practice. It included only men, lasted one week per treatment, and was not designed to assess myocardial infarction, hospitalization or survival.

The 1994 Open Study

Dwivedi and Agarwal studied bark powder for three months in 20 patients: 15 with stable angina and five with unstable angina (Journal of the Association of Physicians of India, 1994; PMID: 7741874). The stable-angina group had fewer episodes and improved treadmill findings, whereas the unstable-angina group did not show a significant reduction and required conventional antianginal medicines. Because the study was open and uncontrolled, it is supportive but not confirmatory.

The 2014 Systematic Review and Meta-analysis

Kaur and colleagues reviewed trials of arjuna in chronic stable angina (Cardiology Research and Practice, 2014; PMID: 24600529). They found poor methodological quality and no significant pooled difference for outcomes that could be meta-analyzed. Their conclusion was that the evidence was insufficient to draw a definite conclusion either for or against arjuna, and that larger, well-controlled multicenter trials were required.

Clinical Evidence: Chronic Heart Failure

Heart-failure research includes one modern randomized trial and one much smaller older study. The more rigorous trial did not improve left ventricular ejection fraction, while some secondary or post-hoc measures suggested possible functional benefit.

The 2016 Randomized Controlled Trial

Maulik and colleagues enrolled 100 patients with chronic heart failure in a double-blind randomized trial published in Phytomedicine in 2016 (PMID: 26988798). A standardized water extract of arjuna bark, 750 mg twice daily, or placebo was added to standard treatment for 12 weeks.

• Arjuna did not produce a significant improvement in left ventricular ejection fraction compared with placebo.
• Post-hoc analyses found greater improvement in six-minute walk distance, antioxidant measures and selected symptom-related quality-of-life domains among some participants.
• Adverse-event rates were not reported as significantly different between the groups.

The study does not establish that arjuna remodels the heart or alters heart-failure prognosis. Its more favorable findings were secondary and partly post-hoc, so they should be treated as hypothesis-generating.

The 1995 Severe Heart Failure Study

Bharani, Ganguly and Bhargava evaluated 12 patients with severe refractory heart failure in an initial placebo-controlled phase, followed by open long-term use of arjuna alongside conventional treatment (International Journal of Cardiology, 1995; PMID: 7649665). Symptoms, effort tolerance, New York Heart Association class and several echocardiographic measures improved during arjuna treatment. The very small sample, older background therapy and open follow-up prevent confident conclusions about efficacy or long-term safety.

Cholesterol, Inflammation and Platelet Findings

Short clinical studies have reported changes in lipid and biological risk markers, but they do not demonstrate prevention of cardiovascular events. Mechanistic findings should not be converted into claims that arjuna has statin-like, antiplatelet-drug-like or anti-inflammatory-drug-like clinical efficacy.

In a randomized controlled trial of 105 patients with coronary heart disease, Gupta and colleagues assigned 35 participants each to placebo, vitamin E 400 units daily or arjuna bark powder 500 mg daily for 30 days (Journal of the Association of Physicians of India, 2001; PMID: 11225136). The arjuna group had mean reductions of about 9.7% in total cholesterol and 15.8% in LDL cholesterol, while lipid-peroxide levels also fell. The short duration, modest group size and absence of clinical-event outcomes mean that this result cannot substitute for evidence supporting prescribed lipid-lowering therapy.

A 2015 adjunctive study in stable coronary artery disease (PMID: 25827448) reported attenuation of selected inflammatory and immune-imbalance markers with Terminalia arjuna. A separate 2009 laboratory study using samples from healthy volunteers and patients with coronary artery disease found reduced platelet activation (PMID: 19437336). Neither study established fewer heart attacks, strokes or bleeding events.

How Arjuna Compares with Standard Cardiac Treatment

Arjuna and guideline-directed cardiovascular medicines do not have comparable evidence bases. Established therapies are selected according to diagnosis and have large randomized trials and guideline recommendations; arjuna has small studies focused mainly on symptoms, exercise tests, ejection fraction and laboratory markers.

Medical Disclaimer: Do not replace beta-blockers, nitrates, antiplatelet medicines, anticoagulants, statins, ACE inhibitors, ARBs, ARNIs, mineralocorticoid antagonists, SGLT2 inhibitors or any other prescribed cardiac treatment with arjuna. Discuss any arjuna product with a cardiologist and a qualified Ayurvedic practitioner. New, severe or worsening chest pain, breathlessness, fainting or symptoms occurring at rest require urgent medical assessment.

Dosage, Traditional Preparation and Safety

Arjuna bark powder, milk decoctions and commercial extracts are not interchangeable. Their concentrations and chemical profiles differ, and the dose used in a clinical trial applies only to the tested preparation. Self-treatment is particularly inappropriate for anyone with diagnosed heart disease or multiple medicines.

Ayurvedic Dose and Arjuna Ksheerapaka

The Ayurvedic Pharmacopoeia of India lists 3–6 g of stem-bark powder. Arjuna ksheerapaka, a milk-based preparation, is taught in Ayurvedic pharmaceutics, but published descriptions document more than one textual method and more than one bark-to-milk-to-water ratio. A single household recipe should therefore not be presented as universally classical. Preparation, dose, timing and suitability should be determined by a qualified practitioner, especially for people who must restrict fluid, sodium, potassium, sugar or dairy intake.

Clinical-Trial Doses

The angina crossover trial used 500 mg of bark extract every eight hours for one week, while the heart-failure trial used 750 mg of standardized water extract twice daily for 12 weeks. These regimens do not establish a general-purpose supplement dose, and products that do not match the trial extracts cannot be assumed to produce the same effects.

Safety and Interaction Considerations

Small trials generally describe arjuna as reasonably tolerated over their study periods, but this is not proof of long-term safety. Reviews have repeatedly noted limited safety data and inadequate standardization across preparations.

• Antiplatelet or anticoagulant treatment: Laboratory evidence of reduced platelet activation creates a plausible interaction concern, although clinical bleeding risk has not been established. A prescriber should review combined use with aspirin, clopidogrel, warfarin, direct oral anticoagulants or similar medicines.
• Blood-pressure and heart medicines: Preclinical cardiovascular effects and use alongside multiple cardiac drugs justify monitoring rather than assuming compatibility.
• Thyroid disease: An animal study reported changes in thyroid hormones during arjuna exposure. A human interaction with levothyroxine or antithyroid treatment has not been established, so clinician review is appropriate.
• Product quality: Use authenticated stem-bark products made under appropriate quality standards. Avoid unlabeled powders, proprietary mixtures with undisclosed quantities and products making claims to replace prescribed treatment.
• Follow-up: Blood pressure, symptoms and relevant laboratory tests should be monitored according to the person’s diagnosis and medication regimen.

Where the Evidence Stands

Arjuna has a verified place in Ayurvedic materia medica: the pharmacopoeial bark is kashaya in rasa, ruksha in guna, shita in virya and katu in vipaka, with hridya, kaphahara and pittahara among its listed actions and hridroga among its uses. Its modern cardiovascular evidence, however, is not strong enough to support routine substitution for proven treatment.

The most defensible interpretation is that arjuna is a research-worthy adjunct. A short angina trial found symptomatic and treadmill benefits, but the systematic review was inconclusive. The principal heart-failure trial did not improve ejection fraction. A short lipid trial reported moderate biochemical changes, while anti-inflammatory and platelet findings remain surrogate or laboratory evidence.

Future trials need standardized, chemically characterized preparations; adequate sample sizes; longer follow-up; transparent adverse-event reporting; and hard outcomes such as myocardial infarction, stroke, heart-failure hospitalization and cardiovascular mortality. Until such data exist, arjuna should be used only within coordinated care from a qualified Ayurvedic practitioner and the patient’s healthcare provider.

References

1. Ayurvedic Pharmacopoeia of India
2. Characterisation of Polyphenols in Terminalia arjuna Bark Extract (2012), PubMed Central
3. Terminalia arjuna in cardiovascular diseases: making the transition from traditional to modern medicine in India (2010), PubMed
4. Short-Term Adjuvant Therapy with Terminalia arjuna Attenuates Ongoing Inflammation and Immune Imbalance in Patients with Stable Coronary Artery Disease: In Vitro and In Vivo Evidence (2015), PubMed
5. Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate (2002), PubMed
6. Antianginal and cardioprotective effects of Terminalia arjuna, an indigenous drug, in coronary artery disease (1994), PubMed
7. Terminalia arjuna in Chronic Stable Angina: Systematic Review and Meta-Analysis (2014), PubMed
8. Clinical efficacy of water extract of stem bark of Terminalia arjuna (Roxb. ex DC.) Wight & Arn. in patients of chronic heart failure: a double-blind, randomized controlled trial (2016), PubMed
9. Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure (1995), PubMed
10. Antioxidant and hypocholesterolaemic effects of Terminalia arjuna tree-bark powder: a randomised placebo-controlled trial (2001), PubMed
11. Inhibitory effects of Terminalia arjuna on platelet activation in vitro in healthy subjects and patients with coronary artery disease (2009), PubMed
12. Terminalia arjuna in coronary artery disease: ethnopharmacology, pre-clinical, clinical & safety evaluation (2014), PubMed
13. Cardio-protective role of Terminalia arjuna bark extract is possibly mediated through alterations in thyroid hormones (2006), PubMed
14. Worldwidejournals (worldwidejournals.com)
15. Professional (professional.heart.org)
16. Professional (professional.heart.org)
17. Heart (heart.org)

Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.